8
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      Analysis of mulberry leaf components in the treatment of diabetes using network pharmacology

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          <p class="first" id="d1937239e166">Mulberry leaves are one of the most commonly used medicinal and herbaceous traditional Chinese medicines that are currently considered for the treatment of diabetes mellitus and its complications. The alkaloids, flavonoids, and polysaccharides in mulberry leaves impart regulatory effects on blood sugar levels. To identify the hypoglycemia-related active components in mulberry leaves and their targets, the present study conducted gas chromatography-mass spectrometer (GC/MS), which identified 202 components of mulberry leaf, of which 22 components may have significant curative effects on diabetes mellitus and its complications and chronic inflammation. The network-based pharmacological analysis platform was used to identify target proteins related to diabetes. Finally, the interaction networks of these target proteins were identified using STRING and Cytoscape. The results showed that mulberry leaf powder contains tricetin, gallic acid, chlorogenic acid, and other drug components that can regulate tumor necrosis factor (TNF), peroxisome proliferator-activated receptor gamma (PPARG), glycogen synthase kinase-3 beta (GSK3B), insulin receptor substrate 1 (IRS1), interleukin 6 (IL-6) and other proteins, which are related to the insulin and inflammatory signaling pathways, glucose metabolism and other related pathways, chronic inflammatory diseases, obesity, diabetic nephropathy, non-insulin-dependent diabetes mellitus and other diseases. </p>

          Related collections

          Author and article information

          Journal
          European Journal of Pharmacology
          European Journal of Pharmacology
          Elsevier BV
          00142999
          August 2018
          August 2018
          : 833
          : 50-62
          Article
          10.1016/j.ejphar.2018.05.021
          29782863
          a73afcad-19d0-4491-8236-f4726ca63c9c
          © 2018

          https://www.elsevier.com/tdm/userlicense/1.0/

          History

          Comments

          Comment on this article